Nab-rapamycin

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameNab-rapamycin
Drug Alias Name西罗莫司白蛋白结合型纳米颗粒Sirolimus albumin boundNab-sirolimusFyarroTARZIFYX +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase mTOR inhibitorsMUT gene stimulantsImmunosuppressants +[4] 
TargetsSerine/threonine-protein kinase mTORMethylmalonyl-CoA Mutase
Therapy Area/IndicationsSolid tumoursDrug Resistant EpilepsyLeigh Disease +[36] 
Global Approved IndicationsPerivascular Epithelioid Cell Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/11/22
Country/TerritoryUnited StatesPuerto RicoSouth Korea
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAbraxis Bioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesAadi Subsidiary IncBiodexa Pharmaceuticals PLCNational Cancer Institute +[6] 
Inactive CompaniesRapamycin Holdings, Inc. Dba Emtora BiosciencesAadi LlcCelgene Corp +[4] 
Active IndicationsSolid tumoursDrug Resistant EpilepsyHypertension, Pulmonary +[26] 
Inactive IndicationsLeigh DiseaseUrinary Bladder NeoplasmsProstatic Neoplasms +[10] 

Other Information

ATC CodeL04AA
Related LinksN/A